Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

US6979691B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Guixue Yu · Wakefield, US
• John E. Macor · Guilford, US
• Timothy Herpin · Princeton, US
• R. Michael Lawrence · Yardley, US
• George C. Morton · Collegeville, US
• Rejean Ruel · Salaberry-de-Valleyfield, CA
• Graham S. Poindexter · Old Saybrook, US
• Edward H. Ruediger · Saint-Lambert, CA
• Carl Thibault · Mascouche, CA

Key dates

• Filing date: Mar 4, 2002
• Grant date: Dec 27, 2005
• Expiry date: Mar 4, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof,in which E is X is N or CH, W is —NR16R17, —NR16C(═O)R22, —NR16CO2R22, —OR23, or a heteroaryl or heterocyclo group as defined in the specification, and R1 through R12, R16, R17, R22, R23, x, y, and z are as defined in the specification, are useful as modulaters of melanocortin receptors, particularly MC-1R and MC-4R.